cefepime and Purpura--Thrombocytopenic--Idiopathic

cefepime has been researched along with Purpura--Thrombocytopenic--Idiopathic* in 1 studies

Other Studies

1 other study(ies) available for cefepime and Purpura--Thrombocytopenic--Idiopathic

ArticleYear
A Case of Cefepime-Induced Immune Thrombocytopenia.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:4

    Drug-induced immune thrombocytopenia (DITP) is a rare adverse event. It is often diagnosed using clinical risk criteria, but this can create diagnostic uncertainty.. A 35-year-old man with disseminated Serratia marcescens infection developed severe thrombocytopenia. A drug-dependent platelet-reactive antibody test demonstrated cefepime-dependent platelet-reactive antibodies which confirmed the diagnosis of DITP.. We describe the first case of cefepime-induced DITP confirmed by a drug-dependent platelet-reactive antibody test. To our knowledge, this is the first proven example of DITP in a fourth-generation cephalosporin.

    Topics: Adult; Blood Platelets; Cefepime; Humans; Male; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia

2022